Quidelortho Corp
F:QL1A
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.9
43.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Quidelortho Corp
QuidelOrtho Corporation has emerged as a significant player in the realm of diagnostic healthcare, formed through the strategic merger of Quidel Corporation and Ortho Clinical Diagnostics. This union brought together Quidel's expertise in rapid diagnostic testing solutions and Ortho Clinical's strengths in in vitro diagnostics, aiming to create a powerhouse capable of addressing the evolving needs of modern healthcare systems globally. Quidel, originally known for its swift point-of-care diagnostic tools for infectious and other diseases, found a strategic complement in Ortho Clinical's laboratory-based testing and transfusion medicine capabilities. This merger allowed QuidelOrtho to leverage both companies’ technological innovations and established customer bases, effectively broadening their market reach and ensuring a diversified revenue stream.
The company operates by developing, manufacturing, and marketing a comprehensive range of diagnostic solutions that serve both healthcare professionals and patients alike. At the heart of QuidelOrtho's operations is its commitment to enhancing patient outcomes through precision testing—a focus that aligns with the growing demand for accurate and reliable diagnostic information. Revenue generation stems from its extensive portfolio, which includes point-of-care testing kits, laboratory instruments, and other diagnostic equipment. By providing indispensable tools that aid in the early detection and management of diseases, QuidelOrtho not only supports healthcare providers in improving clinical outcomes but also positions itself as a crucial contributor to the global medical landscape. Its varied product lines and strategic innovations continue to reinforce its role in promoting public health and advancing medical diagnostics.
QuidelOrtho Corporation has emerged as a significant player in the realm of diagnostic healthcare, formed through the strategic merger of Quidel Corporation and Ortho Clinical Diagnostics. This union brought together Quidel's expertise in rapid diagnostic testing solutions and Ortho Clinical's strengths in in vitro diagnostics, aiming to create a powerhouse capable of addressing the evolving needs of modern healthcare systems globally. Quidel, originally known for its swift point-of-care diagnostic tools for infectious and other diseases, found a strategic complement in Ortho Clinical's laboratory-based testing and transfusion medicine capabilities. This merger allowed QuidelOrtho to leverage both companies’ technological innovations and established customer bases, effectively broadening their market reach and ensuring a diversified revenue stream.
The company operates by developing, manufacturing, and marketing a comprehensive range of diagnostic solutions that serve both healthcare professionals and patients alike. At the heart of QuidelOrtho's operations is its commitment to enhancing patient outcomes through precision testing—a focus that aligns with the growing demand for accurate and reliable diagnostic information. Revenue generation stems from its extensive portfolio, which includes point-of-care testing kits, laboratory instruments, and other diagnostic equipment. By providing indispensable tools that aid in the early detection and management of diseases, QuidelOrtho not only supports healthcare providers in improving clinical outcomes but also positions itself as a crucial contributor to the global medical landscape. Its varied product lines and strategic innovations continue to reinforce its role in promoting public health and advancing medical diagnostics.
Core Growth: Organic sales grew 5% in Q3, excluding COVID and U.S. donor screening, highlighting ongoing strength in core businesses.
Profitability: Adjusted EBITDA rose to $177 million with a 25% margin, up 180 bps year-over-year despite lower respiratory revenue.
Cost Savings: Margin improvement initiatives have delivered over $140 million in cost savings to date.
Guidance Narrowed: Full-year 2025 revenue now expected between $2.68 billion and $2.74 billion; adjusted EBITDA guidance narrowed but midpoint unchanged.
EPS Guidance Lowered: Adjusted EPS for 2025 now expected at $2 to $2.15, reflecting higher interest expenses and taxes.
COVID and Donor Screening: COVID revenue down sharply; U.S. donor screening business winding down and expected to fully exit in H1 2026.
Pipeline Progress: High-sensitivity troponin assay for VITROS cleared by FDA; next-generation instrument in early development.
International Growth: Strongest Q3 growth in Latin America (21%), with mid-single-digit gains in Asia Pacific and EMEA.
